Practice Parameter Contact Dermatitis: A Practice ParametereUpdate 2015 Luz Fonacier, MD, David I. Bernstein, MD, Karin Pacheco, MD, D. Linn Holness, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard Nicklas, MD, John Oppenheimer, MD, Jay Portnoy, MD, Christopher Randolph, MD, Diane Schuller, MD, Sheldon Spector, MD, Stephen Tilles, MD, and Dana Wallace, MD This parameter was developed by the Joint Task Force on Practice Parameters, which represents the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing “Contact Dermatitis: A Practice ParametereUpdate 2015.” This is a complete and comprehensive document at the current time. The medical environment is changing and not all recommendations will be appropriate or applicable to all patients. Because this document incorporated the efforts of many participants, no single individual, including members serving on the Joint Task Force, are authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information or interpretation of this practice parameter by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by the pharmaceutical industry in drug development or promotion. Previously published practice parameters of the Joint Task Force on Practice Parameters for Allergy & Immunology are available at http://www.JCAAI.org or http://www.allergyparameters.org. Ó 2015 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2015;3:S1-S39) Key words: Allergic contact dermatitis; patch testing; allergen; parameter; guideline; contact dermatitis; occupational; sensitizer PREFACE The Practice Parameter on Contact Dermatitis (CD) was last updated in 2006, and focused primarily on the basics of CD and patch testing for the allergist. In the ensuing years, there has been considerable interest by the allergist in allergic skin diseases due to increasing numbers of referrals for CD. With the ease of application, the use of the preloaded commercially available T.R.U.E. Test patch testing method has increased among aller- gists, as has the use of patch testing with individually loaded chambers. The T.R.U.E. Test has also been expanded to include 35 antigens and a negative control, improving their sensitivity to detect inclusive allergens. There have also been advances in the field in many areas including our basic understanding of type IV hypersensitivity reactions, emerging contact allergens, irritant contact dermatitis (ICD), systemic contact dermatitis (SCD), patch testing in children, occupational dermatitis, and reactions to biomedical devices. Improved diagnosis and management of CD and availability of more comprehensive databases of causa- tive contact allergens enable physicians to manage allergic contact dermatitis (ACD) with avoidance of allergens the patient is sensitized to and availability of lists of safe products that do not contain these allergens. Given the many advances in the field, the Joint Task Force on Practice Parameters (JTF) appointed a working group to review and update the standing practice parameters. The Contact Dermatitis: A Practice ParametereUpdate 2015 workgroup was commissioned by the JTF to develop a practice parameter that addresses recent advances in the field of CD and the optimal methods of diagnosis and management based on an assessment of the most current literature. The Chair (Luz Fonacier, MD) invited workgroup members to participate in the parameter development who are considered to be experts in the field of CD. Workgroup members have been vetted for conflict of interest (COI) by the JTF and their COIs have been listed in this document and are posted on the JTF web site at http://www. allergyparameters.org. The charge of the workgroup was to develop current practice guidelines based on an up-to-date systematic literature review. Consensus expert opinion and workgroup-identified supplementary documents were utilized when published evidence was lacking. A search of the medical literature on PubMed was performed for a variety of terms that were considered to be relevant to this See Appendix A for members of the Joint Task Force Contact Dermatitis Parameter Workgroup, reviewers of this Practice Parameter, and members of the Joint Task Force on Practice Parameters. Disclosure of potential conflict of interest: L. Fonacier has received research and educational grants (made to Winthrop University Hospital) from Genentech, Merck, and Baxter; is in the Speaker’s Bureau/Honoraria of Baxter; and is on the Board of Directors, Joint Council of Allergy, Asthma and Immunology (JCAAI) 2012-2015. D. Bernstein is the consultant in Merck, Genentech, Proctor and Gamble, Sanofi, and TEVA; and has received research grants from Amgen, GlaxoSmithKline, Greer, Johnson & Johnson, Merck, Teva, Pfizer, Genentech, Array, Cephalon, Novartis, Boeringer Ingelheim, and Medimmune. The rest of the authors declare that they have no relevant conflicts of interest. The Joint Task Force recognizes that experts in a field are likely to have interests that could come into conflict with the development of a completely unbiased and objective practice parameter. To take advantage of that expertise, a process has been developed to prevent potential conflicts from influencing the final document in a negative way. At the workgroup level, members who have a potential conflict of interest either do not participate in discussions concerning topics related to the potential conflict or if they do write a section on that topic, the workgroup completely rewrites it without their involvement to remove potential bias. In addition, the entire docu- ment is then reviewed by the Joint Task Force and any apparent bias is removed at that level. Finally, the practice parameter is sent for review both by invited re- viewers and by anyone with an interest in the topic by posting the document on the web sites of the ACAAI and the AAAAI. Corresponding author: Joint Task Force on Practice Parameters, 59 N Brockway St, #304, Palatine, IL 60067. E-mail: [email protected]. Received for publication February 25, 2015; accepted for publication February 26, 2015. 2213-2198 Ó 2015 American Academy of Allergy, Asthma & Immunology http://dx.doi.org/10.1016/j.jaip.2015.02.009 S1
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Related Documents
